NO951645L - Syklopeptider - Google Patents

Syklopeptider

Info

Publication number
NO951645L
NO951645L NO951645A NO951645A NO951645L NO 951645 L NO951645 L NO 951645L NO 951645 A NO951645 A NO 951645A NO 951645 A NO951645 A NO 951645A NO 951645 L NO951645 L NO 951645L
Authority
NO
Norway
Prior art keywords
integrins
aminomethyl
leu
gly
beta
Prior art date
Application number
NO951645A
Other languages
English (en)
Other versions
NO951645D0 (no
NO311892B1 (no
Inventor
Alfred Jonczyk
Gunter Holzemann
Simon Goodmann
Horst Kessler
Roland Haubner
Jochen Wermuth
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO951645D0 publication Critical patent/NO951645D0/no
Publication of NO951645L publication Critical patent/NO951645L/no
Publication of NO311892B1 publication Critical patent/NO311892B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/27—Cyclic peptide or cyclic protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO19951645A 1994-04-30 1995-04-28 Syklopeptider, fremgangsmåte for fremstilling derav, farmasöytiske preparater, fremgangsmåte for fremstilling derav,samt anvendelse av forbindelsene NO311892B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4415310A DE4415310A1 (de) 1994-04-30 1994-04-30 Cyclopeptide

Publications (3)

Publication Number Publication Date
NO951645D0 NO951645D0 (no) 1995-04-28
NO951645L true NO951645L (no) 1995-10-31
NO311892B1 NO311892B1 (no) 2002-02-11

Family

ID=6516993

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19951645A NO311892B1 (no) 1994-04-30 1995-04-28 Syklopeptider, fremgangsmåte for fremstilling derav, farmasöytiske preparater, fremgangsmåte for fremstilling derav,samt anvendelse av forbindelsene

Country Status (21)

Country Link
US (1) US5693612A (no)
EP (1) EP0683173B1 (no)
JP (1) JP3711154B2 (no)
KR (1) KR100360831B1 (no)
CN (1) CN1161374C (no)
AT (1) ATE183199T1 (no)
AU (1) AU697614B2 (no)
CA (1) CA2148194C (no)
CZ (1) CZ286705B6 (no)
DE (2) DE4415310A1 (no)
DK (1) DK0683173T3 (no)
ES (1) ES2137394T3 (no)
GR (1) GR3031696T3 (no)
HU (1) HU216795B (no)
NO (1) NO311892B1 (no)
PL (1) PL181272B1 (no)
RU (1) RU2151776C1 (no)
SK (1) SK281843B6 (no)
TW (1) TW354790B (no)
UA (1) UA46699C2 (no)
ZA (1) ZA953467B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244622B2 (en) * 1996-04-03 2007-07-17 Applera Corporation Device and method for multiple analyte detection
DE19736772A1 (de) * 1997-08-23 1999-02-25 Merck Patent Gmbh Cyclopeptidderivate
WO2000038715A2 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and radiation in the treatment of neoplasia
NZ528076A (en) * 2001-03-02 2005-09-30 Medimmune Inc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists with an immunomodulatory agents, anti-inflammatory agents, TNF-alpha antagonists or CD2 binding molecules
JP2005533001A (ja) * 2002-03-04 2005-11-04 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
EP2270049A3 (en) 2002-04-12 2011-03-09 Medimmune, Inc. Recombinant anti-interleukin-9-antibody
EP1596884A2 (en) * 2003-01-30 2005-11-23 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
CN100429223C (zh) * 2004-02-06 2008-10-29 南京工业大学 环(d-苯丙-d-组)二肽的制备方法
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
MXPA06014092A (es) 2004-06-04 2007-03-15 Scripps Research Inst Composiciones y metodos para el tratamiento de enfermedades neovasculares.
EP1810028A2 (en) * 2004-10-14 2007-07-25 Rigel Pharmaceuticals, Inc. Heterocyclic inhibitors of ires-mediated translation and methods of use thereof
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
DE602004030494D1 (de) * 2004-10-30 2011-01-20 Univ Pais Vasco B-lactam-rgd-cyclopeptide mit gamma-(g-)wendungen
AU2007272970C1 (en) 2006-07-11 2013-01-10 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
PT2068889T (pt) 2006-08-10 2020-01-30 Roy C Levitt Anakinra para uso no tratamento da síndrome da bronquiolite obliterante
ES2634431T3 (es) * 2009-03-16 2017-09-27 The Governing Council Of The University Of Toronto Moléculas de aminoácidos cíclicos y procedimientos de preparación de las mismas
ES2898844T3 (es) * 2015-09-18 2022-03-09 Univ Muenchen Tech Ligandos para integrina alphavbeta6, síntesis y usos de los mismos
EP3377471A4 (en) 2015-11-11 2019-11-20 Encycle Therapeutics, Inc. FRAGMENT SYNTHESIS OF CYCLIC PEPTIDES
EP3939989A1 (en) 2016-11-11 2022-01-19 Zealand Pharma A/S Cyclic peptides multimers targeting alpha 4beta 7 integrin
EP3388445A1 (en) * 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Peptide macrocycles and use thereof in the treatment of bacterial infections
KR20200015540A (ko) 2017-05-10 2020-02-12 인사이클 세라퓨틱스, 인코포레이티드 α4β7 인테그린을 타겟팅하는 호모데틱 사이클릭 펩타이드

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472305A (en) * 1983-05-17 1984-09-18 Sterling Drug Inc. Hexapeptide amides
DE3703159A1 (de) * 1987-02-03 1988-08-11 Hoechst Ag Cyclische peptide mit cytoprotektiver wirkung
JP2945680B2 (ja) * 1988-09-09 1999-09-06 旭硝子株式会社 ペプチド誘導体およびその用途
DE3915361A1 (de) * 1989-05-11 1990-11-15 Merck Patent Gmbh Cyclopeptide
US5192746A (en) * 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
DK0578728T3 (da) * 1991-04-05 1999-04-12 Genentech Inc Inhibitorer for aggregering af blodplader, hvilke inhibitorer har høj specificitet for GP IIbIIIa
EP0528312B1 (en) * 1991-08-13 1997-07-16 Takeda Chemical Industries, Ltd. Cyclic peptides and use thereof
IL103252A (en) * 1991-09-30 1997-03-18 Du Pont Merck Pharma CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UA43823C2 (uk) * 1992-07-06 2002-01-15 Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ІНТЕГРИН <font face="Symbol">a</font><sub>V</sub><font face="Symbol">b</font><sub>3</sub>-ОПОСЕРЕДКОВАНОЇ КЛІТИННОЇ АДГЕЗІЇ КЛІТИН ССАВЦІВ, СПОСІБ ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ЗАХВОРЮВАННЯ, АСОЦІЙОВАНОГО З ПОРУШЕННЯМ АДГЕЗІЇ КЛІТИН, СПОСІБ БЛОКУВАННЯ ЗВ'ЯЗУВАННЯ ФІБРИНОГЕНОМ ІНТЕГРИНУ, КОМПОЗИЦІЯ ДЛЯ ЗАГОЄННЯ РАН
DE4310643A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren

Also Published As

Publication number Publication date
AU697614B2 (en) 1998-10-15
CN1161374C (zh) 2004-08-11
NO951645D0 (no) 1995-04-28
TW354790B (en) 1999-03-21
CA2148194A1 (en) 1995-10-31
CA2148194C (en) 2007-04-10
SK281843B6 (sk) 2001-08-06
HU9501253D0 (en) 1995-06-28
EP0683173B1 (de) 1999-08-11
PL181272B1 (pl) 2001-07-31
DE59506568D1 (de) 1999-09-16
JP3711154B2 (ja) 2005-10-26
EP0683173A1 (de) 1995-11-22
ZA953467B (en) 1996-01-17
DE4415310A1 (de) 1995-11-02
PL308420A1 (en) 1995-11-13
JPH07304795A (ja) 1995-11-21
RU95106821A (ru) 1997-01-10
US5693612A (en) 1997-12-02
CN1116628A (zh) 1996-02-14
AU1772495A (en) 1995-11-09
GR3031696T3 (en) 2000-02-29
HUT75057A (en) 1997-03-28
CZ107395A3 (en) 1995-11-15
UA46699C2 (uk) 2002-06-17
ATE183199T1 (de) 1999-08-15
ES2137394T3 (es) 1999-12-16
SK55895A3 (en) 1995-12-06
HU216795B (hu) 1999-08-30
RU2151776C1 (ru) 2000-06-27
KR100360831B1 (ko) 2003-01-24
KR950032275A (ko) 1995-12-20
DK0683173T3 (da) 2000-03-13
NO311892B1 (no) 2002-02-11
CZ286705B6 (en) 2000-06-14

Similar Documents

Publication Publication Date Title
NO951645D0 (no) Syklopeptider
DE69939705D1 (de) Behandlung der pompeschen krankheit
ATE403677T1 (de) Beschleuniger des plättchenwachstums
DE69738615D1 (de) Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
ITMI922953A1 (it) Inibitori a doppia attivita&#39; biologica di no sintasi e cicloossigenasi procedimento per la loro preparazione e composizioni terapeutiche che li contengono.
IL112111A0 (en) Peptide derivatives and pharmaceutical compositions containing them
DE4394931T1 (de) Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
DE59606784D1 (de) Verwendung von boswelliasäure und ihren derivaten zur hemmung der normalen und gesteigerten leukozytenelastase- oder plasminaktivität
AR002245A1 (es) Antagonistas del receptor de adhesion, procedimiento para prepararlos, preparaciones farmaceuticas que los contienen y el empleo de los mismos parapreparar medicamentos.
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
MA20919A1 (fr) Procede de preparation d&#39;inhibiteurs de l&#39;enzyme de conversion de l&#39;angiotensine
DE69426897D1 (de) Antithrombotisch wirkende azacycloalkyl-alkanoyl-peptide und-pseudopeptide
JPH04182420A (ja) 歯周疾患の予防ならびに治療剤
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
RU97112901A (ru) Тромболитические средства
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
DE69420574D1 (de) Derivate von therapeutisch in der blutgerinnungskaskade wirksamen peptiden, verfahren zur herstellung und sie enthaltende pharmazeutische zubereitungen
RU94044487A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия
ATE49958T1 (de) Pharmazeutische zusammensetzungen mit immunodepressivwirkung.
MX9601659A (es) Antagonistas del receptor de adhesion, procedimiento para prepararlos, composiciones farmaceuticas que los contienen y su empleo para preparar medicamentos y combatir enfermedades.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees